| 包装 | 价格(元) |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
Cell lines | Parental A2780 cells and A2780-CDDP resistant cells |
Preparation method | This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 ℃ for several months. |
Reacting condition | 0.1, 0.3, 1 or 5 μM; 48 hrs |
Applications | At the moderate dose of 5 μM, SGI-110 increased the sensitivity of OC cells to CDDP, resulting in a >2-fold reduction in the IC50 for CDDP: 28 μM CDDP IC50 for A2780-CDDP resistant cells and 42 μM CDDP IC50 for parental A2780 cells. SGI-110 increased the sensitivity of both the parental and the resistant A2780 cells to CDDP. It was demonstrated that SGI-110 chemosensitized the A2780 cells by demethylation and reexpression of MLH1, RASSF1A and HOXA11. |
Animal models | Nude rats bearing Calu6 cells |
Dosage form | 20 mg/kg; s.c.; twice per week, for 4 weeks |
Applications | In nude rats bearing Calu6 cells, SGI-110 alone reduced tumor burden by 35%, and the combination treatment with SGI-110 ﹢ Entinostat significantly reduced tumor burden by 56%. Besides, SGI-110 alone or in combination with Entinostat decreased the pleomorphic cell population similarly, to approximately 25%. However, compared with the control group, these 2 treatment groups showed some cumulative toxicity. After 4 weeks of treatment, body weights of rats reduced by 13 ~ 18%. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| 产品描述 | SGI-110 is a second generation DNA methyltransferase (DNMT) inhibitor that is synthesized as a dinucleotide consisting of a deoxyguanosine (5’-DACpG-3’) and 5-AZA-CdR bonds with a natural phosphodiester linkage. Unlike other DNMT inhibitors that are susceptible to rapid inactivation by cytidine deaminase (CDA), SGI-110 is highly resistant to deamination by CDA. In previous studies, SGI-110 has been demonstrated to effectively retard tumor growth in human bladder cancer xenografts through both intraperitoneal (i.p.) and subcutaneous (s.c.) administration and to exhibit epigenetic remodeling activity, in which the expression of p16 in cancer cells is restored through demethylation of the 5’-end region of the gene. References: |
m.cnreagent.com